Pacira BioSciences, Inc.
PCRX
$23.04
$0.200.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.40% | -89.79% | 103.79% | -125.66% | -46.41% |
| Total Depreciation and Amortization | 0.77% | 26.36% | -22.53% | 44.84% | 14.88% |
| Total Amortization of Deferred Charges | -33.45% | -33.64% | -20.97% | 10.94% | 22.98% |
| Total Other Non-Cash Items | 126.76% | -100.61% | -68.41% | 40.77% | -57.47% |
| Change in Net Operating Assets | -469.05% | 186.97% | -866.04% | -771.20% | -61.36% |
| Cash from Operations | -27.58% | 31.86% | 12.82% | -77.44% | -27.78% |
| Capital Expenditure | 68.13% | 89.71% | 5.43% | -69.62% | -201.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 97.99% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6,036.68% | 1,017.20% | 198.78% | 576.04% | 97.01% |
| Cash from Investing | 175.86% | 5,353.53% | 183.61% | 508.56% | -65.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -77.75% | -77.81% | -10,786.46% | 98.15% | 0.00% |
| Issuance of Common Stock | -- | 84.37% | -- | 15.03% | -- |
| Repurchase of Common Stock | -29,955.25% | -62,745.45% | -156,303.13% | -118.00% | -4,425.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1,883.90% | -2,542.05% | -8,950.12% | -330.20% | -6.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -308.29% | -64.44% | -13,952.85% | -73.22% | -77.77% |